Literature DB >> 29863255

MicroRNA-221: biogenesis, function and signatures in human cancers.

A Abak1, S Amini, E Sakhinia, A Abhari.   

Abstract

MicroRNAs are small non-coding RNAs of 18-25 nucleotides that regulate gene expression at the post-transcriptional level through binding to the 3´-UTR of mRNAs and block mRNA transcription or regulate its resistance. Increasing evidence indicates that dysregulation of miRNA is a hallmark of cancer. The miRNAs have an essential role in the regulation of oncogenes or tumor suppressor genes in cell signaling pathways. MiR-221 and miR-222 are two homologous microRNAs, the high expression levels of which have been commonly demonstrated in multiple human cancer types. The miR-221/miR-222 functions have been verified as oncogenes or tumor suppressors. Here, we reviewed the roles of miR-221/miR-222 in various kinds of cancer progression and development: controlling proliferative signaling pathways, avoiding cell deaths resulted from tumor suppressors, monitoring angiogenesis and even supporting epithelial-mesenchymal transition. We discussed that miR-221/miR-222 act as promising biomarkers for detection of human cancer types and suggested a new pathway for molecular targeted cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29863255     DOI: 10.26355/eurrev_201805_15069

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  MicroRNA-221 promotes proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) by targeting tissue inhibitor of metalloproteinases-3 (TIMP3).

Authors:  Yan Yan; Ying Xu; Gehui Ni; Siqi Wang; Xinli Li; Juan Gao; Haifeng Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2020-08

2.  miR‑139‑3p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A.

Authors:  Wei Zhang; Jing Xu; Ke Wang; Xiaojiang Tang; Jianjun He
Journal:  Oncol Rep       Date:  2019-08-29       Impact factor: 3.906

3.  Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.

Authors:  Jiyoon Kim; Siwoo Cho; Yonghyun Park; Jiyoul Lee; Jaesung Park
Journal:  PLoS One       Date:  2021-12-31       Impact factor: 3.240

Review 4.  miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.

Authors:  Maria Teresa Di Martino; Mariamena Arbitrio; Daniele Caracciolo; Alessia Cordua; Onofrio Cuomo; Katia Grillone; Caterina Riillo; Giulio Caridà; Francesca Scionti; Caterina Labanca; Caterina Romeo; Maria Anna Siciliano; Maria D'Apolito; Cristina Napoli; Martina Montesano; Valentina Farenza; Valentina Uppolo; Michele Tafuni; Federica Falcone; Giuseppe D'Aquino; Natale Daniele Calandruccio; Francesco Luciano; Licia Pensabene; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-11       Impact factor: 8.886

5.  LINC00210 as a miR-328-5p sponge promotes nasopharyngeal carcinoma tumorigenesis by activating NOTCH3 pathway.

Authors:  Shu Zhang; Ping Li; Lei Zhao; Ling Xu
Journal:  Biosci Rep       Date:  2018-11-15       Impact factor: 3.840

6.  LINC02476 Promotes the Malignant Phenotype of Hepatocellular Carcinoma by Sponging miR-497 and Increasing HMGA2 Expression.

Authors:  Yuxia Duan; Mengjing Zhao; Mengmeng Jiang; Zhi Li; Caifang Ni
Journal:  Onco Targets Ther       Date:  2020-04-01       Impact factor: 4.147

7.  LncRNA ITGB2-AS1 promotes the progression of clear cell renal cell carcinoma by modulating miR-328-5p/HMGA1 axis.

Authors:  Wensheng Zhang; Yigang Lu; Huibo Shi; Xungang Li; Zhuo Zhang; Xinxi Deng; Yang Yang; Bin Wan
Journal:  Hum Cell       Date:  2021-06-25       Impact factor: 4.174

8.  Exosomal miR-218-5p/miR-363-3p from Endothelial Progenitor Cells Ameliorate Myocardial Infarction by Targeting the p53/JMY Signaling Pathway.

Authors:  Xiao Ke; Rongfeng Yang; Fang Wu; Xing Wang; Jiawen Liang; Xun Hu; Chengheng Hu
Journal:  Oxid Med Cell Longev       Date:  2021-07-16       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.